Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

SHOCKING: 15 - You Need To See This

Needham Maintains Buy Rating for GLOBALFOUNDRIES: Here's What You Need To Know

Needham has decided to maintain its Buy rating of GLOBALFOUNDRIES (NASDAQ:GFS) and lower its price target from $87.00 to $70.00. Shares of GLOBALFOUNDRIES are trading down 5.06% over the last 24 hours, at $50.06 per share. A move to $70.00 would account for a 39.83% increase from the current share…

Benzinga

3 Block Analysts React To Q1 Earnings Miss, Cash App Growth, Bitcoin Weakness

Block Inc (NYSE: SQ) reported a first-quarter earnings miss driven by a sharp downturn in Bitcoin (CRYPTO: BTC) revenue.

Benzinga

Fubo Shares Bleed As Analysts Re-rate Stock Post Q1 Results

Analysts remained concerned over fuboTV Inc (NYSE:FUBO), as reflected by their re-rating post Q1 results. Needham analyst Laura Martin maintained FuboTV with a Buy and lowered the price target from $15 to $5 (49% upside). Gross margins of negative (2)% were the lowest FUBO had reported since 2Q20 when it only had 286,000 paid subscribers. The…

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Needham Maintains Buy Rating for Selecta Biosciences: Here's What You Need To Know

Needham has decided to maintain its Buy rating of Selecta Biosciences (NASDAQ:SELB) and lower its price target from $7.00 to $6.00. Shares of Selecta Biosciences are trading up 2.84% over the last 24 hours, at $0.83 per share.

Benzinga

'Still A Second-Half Story': Twilio Analysts React To Mixed Q1 Earnings

Twilio Inc (NYSE: TWLO) shares dropped 2.7% on Thursday after the company reported conservative second-quarter guidance.

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For May 6, 2022

Upgrades For Coupang Inc (NYSE:CPNG), JP Morgan upgraded the previous rating of Neutral to Overweight. The stock has a 52-week-high of $46.00 and a 52-week-low of $11.91. At the end of the last trading period, Coupang closed at $11.99.

Benzinga

Needham Maintains Buy Rating for Twilio: Here's What You Need To Know

Needham has decided to maintain its Buy rating of Twilio (NYSE:TWLO) and lower its price target from $350.00 to $200.00. Shares of Twilio are trading down 3.58% over the last 24 hours, at $114.24 per share. A move to $200.00 would account for a 75.07% increase from the current share…

Benzinga

Read news from The Economist, FT, and more,
with one subscription

10 Biggest Price Target Changes For Thursday

Needham cut Cirrus Logic, Inc. (NASDAQ: CRUS) price target from $110 to $100. Cirrus Logic shares rose 4.5% to close at $82.81 on Wednesday.

Benzinga

Read How Analysts Reacted To Paycom Software's Q1 Results

Analysts reiterated their ratings on Paycom Software, Inc (NYSE:PAYC) post Q1 results. Needham analyst Ryan MacDonald reiterated the Buy rating and $450 price target on Paycom Software following the company's stellar start to FY22, in which revenue and adjusted EBITDA exceeded consensus expectations. PAYC put up a sizeable 1Q22 beat and raise driven by solid sales…

Benzinga

AtriCure's Q1 EPS Miss Estimates, Needham Lowers Price Target

Needham lowered AtriCure Inc's (NASDAQ: ATRC) price target to $67 from $79 due to peer multiple compression, with the Buy rating unchanged.

Benzinga

Lyft Analysts React To Q2 Guidance Miss, Heavy Investments In Lagging Driver Recovery

LYFT Inc (NASDAQ: LYFT) shares plummeted 32% on Wednesday after the company issued second-quarter guidance that came up well short of market expectations.

Benzinga

'Pent-Up Demand Driving Strength': Airbnb Analysts React To Q1 Earnings Beat

Airbnb Inc (NASDAQ: ABNB) shares traded higher by 4.9% on Wednesday after the company reported big first-quarter earnings growth and said it expects a sharp rebound in summer travel in 2022 as pandemic headwinds abate.

Benzinga

Needham Maintains Buy Rating for MagnaChip Semiconductor: Here's What You Need To Know

Needham has decided to maintain its Buy rating of MagnaChip Semiconductor (NYSE:MX) and lower its price target from $29.00 to $25.00. Shares of MagnaChip Semiconductor are trading down 4.83% over the last 24 hours, at $17.35 per share.

Benzinga

Masimo Posts Better Than Expected Q1 Earnings Despite 'Unexpected' Supply Chain Issues

Masimo Corp's (NASDAQ:MASI) Q1 revenue increased 1.7% Y/Y (+3.2% on a constant currency basis) to $304.2 million, beating the consensus of $303.83 million. Excluding handheld and fingertip pulse oximeters, shipments of noninvasive technology boards and instruments were 75,700 in Q1 of 2022. The adjusted operating margin remained unchanged at 22.9%. The company reported…

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For May 2, 2022

Upgrades

Benzinga

Why Are Accolade Shares Down Over 40% Today

Accolade Inc (NASDAQ:ACCD) shares plunged almost 50% after disappointing Q4 FY22 earnings and FY23 guidance. Q4 FY22 revenue increased 58% Y/Y to $93.8 million, beating the consensus of $91.57 million. The company reported a wider net loss of $(34.56) million compared to $(4.73) million a year ago. EPS loss came at $(0.51)…

Benzinga

Needham Maintains Buy Rating for Teleflex: Here's What You Need To Know

Needham has decided to maintain its Buy rating of Teleflex (NYSE:TFX) and lower its price target from $400.00 to $355.00. Shares of Teleflex are trading down 1.62% over the last 24 hours, at $290.71 per share. A move to $355.00 would account for a 22.11% increase from the current share…

Benzinga

'Long Road Of Rebuilding Begins': PayPal Analysts React To Mixed Q1 Earnings Report

Shares of PayPal Holdings Inc (NASDAQ: PYPL) gained 11% on Thursday after the company reported a revenue beat but cut its 2022 guidance.

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Teladoc Analysts React To Shocking Q1 Losses, Rising BetterHelp Costs

A brutal 12 months for Teladoc Health Inc (NYSE: TDOC) went from bad to much worse on Thursday when the stock dropped another 43% after the company reported much larger-than-expected losses in the first quarter and slashed its 2022 guidance.

Benzinga

10 Biggest Price Target Changes For Thursday

Needham lowered MKS Instruments, Inc. (NASDAQ: MKSI) price target from $185 to $175. MKS Instruments shares rose 3.6% to $116.01 in pre-market trading.

Benzinga

Needham Maintains Buy Rating for Calix: Here's What You Need To Know

Needham has decided to maintain its Buy rating of Calix (NYSE:CALX) and lower its price target from $73.00 to $60.00. Shares of Calix are trading up 3.28% over the last 24 hours, at $39.34 per share. A move to $60.00 would account for a 52.52% increase from the current share…

Benzinga

Here's Why Analysts Were Impressed Post Cadence Design Systems' Q1 Performance

Cadence Design Systems, Inc (NASDAQ:CDNS) impressed analysts post Q1 beat. Baird reiterated Outperform rating on Cadence, adjudging it as a top idea. All business groups saw strength, with recurring revenues increasing 19% YoY (led by Digital and System Design) and upfront revenues rising 49% YoY. FY22 outlook raised given 1Q strength, upside in 2Q,…

Benzinga

These Netflix Analysts Aren't Confident Of A Turnaround Within The Next 18 Months

Netflix Inc (NASDAQ: NFLX) reported a revenue miss and a loss of net paid adds for the first quarter.

Benzinga

Coinbase And This Cold Wallet Stock Look 'Quite Discounted' Ahead Of Potential Crypto Rally

Bitcoin (CRYPTO: BTC) is down about 10% year-to-date, but several crypto-related stocks have fallen significantly further. Needham & Company's John Todaro offered an explanation for the disconnection Tuesday on CNBC's "TechCheck."

Benzinga

Needham Estimates PhaseBio Pharma's Bentracimab Market Opportunity Of Up To $1.5B

PhaseBio Pharmaceuticals Inc (NASDAQ: PHAS) remains on track to complete the bentracimab biologics license application (BLA) filing around mid-2022 for bleeding risks associated with using ticagrelor antiplatelet drug.

1 … 14 15 16 17

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations